More on RADX
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $4.67 |
|
|||
| Open | $4.64 | ||||
| 52 Wk High | $ | ||||
| 52 Wk Low | $ | ||||
| Day High | $5.12 | ||||
| Day Low | $4.64 | ||||
| P/E | N/A | ||||
| EPS | $ | ||||
| Volume | 129,732 | ||||
- Radiopharm Theranostics doses first patient in cancer drug trial
- Radiopharm Theranostics Doses First Patient in Phase 1/2a Clinical Study of BetaBart (RV-01)
- Radiopharm Theranostics Reports Half-Year Financial Results and Business Updates
- Presenting on Emerging Growth Conference 89 Day 1 on January 21; Register to live stream
- Radiopharm Theranostics increases stake in cancer drug joint venture to 87.5%
- RAD Increases Ownership in Radiopharm Ventures to 87.5%
- Radiopharm Theranostics (RADX) PT Raised to $16 at B.Riley
- Radiopharm reports 92% success rate in brain cancer imaging trial
- Radiopharm Theranostics Achieves Primary Endpoint in 92% of Patients at Interim Analysis of RAD 101 Phase 2b Imaging Trial in Brain Metastases
- Radiopharm Theranostics (RADX) PT Lowered to $13 at B.Riley
Entities mentioned with RADX
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- Deutsche Bank | View Related Stories »
- Definitive Agreement | View Related Stories »
- S1 | View Related Stories »
- Show More...
